Drug Profile

OPM 102

Alternative Names: OPM-102

Latest Information Update: 06 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Oncodesign Precision Medicine
Class Antineoplastics; Small molecules
Mechanism of Action Receptor-interacting protein serine-threonine kinase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

15 Jan 2024 OPM 102 is available for licensing as of 15 Jan 2024. https://www.oncodesign.com/our-pipeline/partnering/
10 Jan 2024 Preclinical trials in Solid tumours in France (unspecified route) prior to January 2024 (Oncodesign Precision Medicine pipeline, January 2024)
10 Jan 2024 Oncodesign Precision Medicine plans to initiate IND-enabling studies in Solid tumours by mid 2024 (Oncodesign Precision Medicine pipeline, January 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com